Welcome to This Week in Rheumatology. This week we're covering 8 notable papers spanning advances in precision monitoring and biomarkers, new insights into long-term risk and disease pathogenesis, and a look at novel therapeutics in related fields. Let's dive in.

This week's papers:

1. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. — The New England journal of medicine 2026
2. Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease. — The New England journal of medicine 2026
3. Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease. — Annals of the rheumatic diseases 2026
4. Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy. — Annals of the rheumatic diseases 2026
5. Carotid-femoral pulse wave velocity improves cardiovascular risk prediction beyond SCORE2 in autoimmune rheumatic diseases: a 7-year follow-up study. — RMD open 2026
6. Risk of chronic kidney disease in newly diagnosed systemic lupus erythematosus with preserved renal function: a national study. — Rheumatology (Oxford, England) 2026
7. [Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker. — RMD open 2026
8. Monogenic autoimmune and autoinflammatory disorders in adulthood: recent discoveries and implications for rheumatology practice. — Rheumatology (Oxford, England) 2026

Listen at AudioScholar